Interferon in chronic myeloid leukaemia: past and future

Best Practice and Research: Clinical Haematology

Volumn 22, Issue 3, 2009, Pages 315-329

  Guilhot, François ^a   Roy, Lydia ^a   Saulnier, Pierre Jean ^a   Guilhot, Joëlle ^a  

^a POITIERS UNIVERSITY HOSPITAL   (France)

Author keywords

chronic myeloid leukaemia; interferon; randomized trials; stem cell dormancy

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; ALPHAN1 INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BUSULFAN; CYTARABINE; CYTARABINE 5' STEARYLPHOSPHATE; GAMMA INTERFERON RECEPTOR 1; HYDROXYUREA; IMATINIB; INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; JANUS KINASE 1; PEGINTERFERON; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEIN KINASE TYK2; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT ALPHA2C INTERFERON; STAT PROTEIN;

AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTINUOUS INFUSION; CYTOPENIA; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG PREFERENCE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOTHYROIDISM; IMMUNOMODULATION; LEUKOPENIA; LOW DRUG DOSE; MONOTHERAPY; MYALGIA; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; HUMANS; INTERFERONS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASTIC STEM CELLS; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 71849105059     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.10.005     Document Type: Review

References (78)

1. Ben-Neriah Y., Daley G.Q., Mes-Masson A.M., et al. The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science 233 (1986) 212-214
2. Shtivelman E., Lifshitz B., Gale R.P., et al. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 315 (1985) 550-554
3. Smit W.M., Rijnbeek M., van Bergen C.A., et al. T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukaemia after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A 95 (1998) 10152-10157
4. Drobyski W.R., Keever C.A., Roth M.S., et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 82 (1993) 2310-2318
5. Kolb H.J., Mittermüller J., Clemm C., et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 76 (1990) 2462-2465
6. Kolb H.J., Schattenberg A., Goldman J.M., et al. Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86 (1995) 2041-2050
7. Aguet M., Grobke M., and Dreiding P. Various human interferon alpha subclasses cross-react with common receptors: their binding affinities correlate with their specific biological activities. Virology 132 (1984) 211-216
8. Merlin G., Falcoff E., and Aguet M. 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data. J Gen Virol 66 (1985) 1149-1152
9. Pfeffer L.M., Dinarello C.A., Herberman R.B., et al. Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res 58 (1998) 2489-2499
10. Gutterman J.U. Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A 91 (1994) 1198-1205
11. Harada H., Taniguchi T., and Tanaka N. The role of interferon regulatory factors in the interferon system and cell growth control. Biochimie 80 (1998) 641-650
12. Siegal F.P., Kadowaki N., Shodell M., et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284 (1999) 1835-1837
13. Nagamura-Inoue T., Tamura T., and Ozato K. Transcription factors that regulate growth and differentiation of myeloid cells. Int Rev Immunol 20 (2001) 83-105
14. Nelson N., Kanno Y., Hong C., et al. Expression of IFN regulatory factor family proteins in lymphocytes. Induction of Stat-1 and IFN consensus sequence binding protein expression by T cell activation. J Immunol 156 (1996) 3711-3720
15. Driggers P.H., Ennist D.L., Gleason S.L., et al. An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. Proc Natl Acad Sci U S A 87 (1990) 3743-3747
16. Weisz A., Marx P., Sharf R., et al. Human interferon consensus sequence binding protein is a negative regulator of enhancer elements common to interferon-inducible genes. J Biol Chem 267 (1992) 25589-25596
17. Schmidt M., Nagel S., Proba J., et al. Lack of interferon consensus sequence binding protein (ICSBP) transcripts in human myeloid leukaemias. Blood 91 (1998) 22-29
18. Schmidt M., Hochhaus A., Nitsche A., et al. Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukaemia correlates with pretreatment risk features and cytogenetic response to interferon-{alpha}. Blood 97 (2001) 3648-3650
19. Hao S.X., and Ren R. Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukaemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol 20 (2000) 1149-1161
20. Tamura T., Kong H.J., Tunyaplin C., et al. ICSBP/IRF-8 inhibits mitogenic activity of p210 Bcr/Abl in differentiating myeloid progenitor cells. Blood 102 (2003) 4547-4554
21. Holtschke T., Lohler J., Kanno Y., et al. Immunodeficiency and chronic myelogenous leukaemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87 (1996) 307-317
22. Deng M., and Daley G.Q. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukaemia. Blood 97 (2001) 3491-3497
23. Asselin-Paturel C., Boonstra A., Dalod M., et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol 2 (2001) 1144-1150
24. Schiavoni G., Mattei F., Sestili P., et al. ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8 alpha(+) dendritic cells. J Exp Med 196 (2002) 1415-1425
25. Sacchi S., Kantarjian H., O'brien S., et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukaemia. J Clin Oncol 13 (1995) 2401-2407
26. Paquette R.L., Hsu N., Said J., et al. Interferon-alpha induces dendritic cell differentiation of CML mononuclearcells in vitro and in vivo. Leukemia 16 (2002) 1484-1489
27. Oka T., Sastry K.J., Nehete P., et al. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia 12 (1998) 155-163
28. Holyoake T., Jiang X., Eaves C., et al. Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukaemia. Blood 94 (1999) 2056-2064
29. Graham S.M., Jorgensen H.G., Allan E., et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood 99 (2002) 319-325
30. Copland M., Hamilton A., Elrick L.J., et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107 (2006) 4532-4539
31. Jiang X., Zhao Y., Smith C., et al. Chronic myeloid leukaemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21 (2007) 926-935
32. Essers M.A., Offner S., Blanco-Bose W.E., et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458 (2009) 904-908
33. Sato T., Onai N., Yoshihara H., et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 15 (2009) 696-700
34. Chawla-Sarkar M., Lindner D.J., Liu Y.F., et al. Apoptosis and interferons: role of interferonstimulated genes as mediators of apoptosis. Apoptosis 8 (2003) 237-249
35. Der S.D., Zhou A., Williams B.R., et al. Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci U S A 95 (1998) 15623-15628
36. Selleri C., Sato T., Del Vecchio L., et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood 89 (1997) 957-964
37. Peschel C., Aulitzky W.E., and Huber C. Influence of interferon-alpha on cytokine expression by the bone marrow microenvironment-impact on treatment of myeloproliferative disorders. Leuk Lymphoma 22 Suppl. 1 (1996) 129-134
38. Bhatia R., and Verfaillie C.M. The effect of interferon-alpha on beta-1 integrin mediated adhesion and growth regulation in chronic myelogenous leukemia. Leuk Lymphoma 28 (1998) 241-254
39. Dowding C., Gordon M., Guo A.P., et al. Potential mechanisms of action of interferon-alpha in CML. Leuk Lymphoma 11 (1993) 185-191
40. Talpaz M., Kantarjian H., McCredie K.B., et al. Clinical investigation of human alpha interferon in chronic myelogenous leukemia. Blood 69 (1987) 1280-1288
41. Kantarjian M., O'Brien S., Anderlini P., et al. Treatment of chronic myelogenous leukemia: current status and investigational options. Blood 87 (1996) 3069-3081
42. Niederle N., Kloke O., Wandl U.B., et al. Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studies. Leuk Lymphoma 9 (1993) 111-119
43. Ozer H., George S., Schiffer C., et al. Prolonged subcutaneous administration of recombinant alpha-2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B Study 8583. Blood 82 (1993) 2975-2984
44. Alimena G., Morra E., Lazzarino, et al. Interferon alpha-2b as therapy for Ph-positive chronic myelogenous leukemia: a study of 82 patients treated with intermittent or daily administration. Blood 72 (1989) 642-647
45. Freund M., Von Wussow P., Diedrich H., et al. Recombinant human interferon(IFN) alpha-2b in chronic myelogenous leukemia. Dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72 (1989) 350-356
46. Schofield J.R., Robinson W.A., Murphy J.R., et al. Low doses of Interferon-* are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med 121 (1994) 736-744
47. Hehlmann R., Heimpel H., Hasford J., et al. Randomized comparison of interferon-a with busulfan and hydroxyurea in chronic myelogenous leukemia (CML). Blood 84 (1994) 4064-4077
48. Allan N., Richards S., Shepherd P., et al. UK Medical Research Council randomized, multicentre trial of interferon-a n1 for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 345 (1995) 1392-1397
49. Ohnishi K., Ohno R., Tomonaga M., et al. A randomized trial comparing interferon-a with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood 86 (1995) 906-916
50. Italian Cooperative Group on Chronic Myeloid Leukemia. Interferon-a-2b compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330 (1994) 820-825
51. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Long-term follow-up of the Italian trial of interferon-a versus conventional chemotherapy in chronic myeloid leukemia. Blood 92 (1998) 1541-1548
52. The Benelux CML Study Group. Randomized study on hydroxyurea alone versus hydroxyurea combined with low dose interferon-alpha2b for chronic myeloid leukemia. Blood 91 (1998) 2713-2721
53. Hehlmann R., Berger U., Pfirrmann M., et al. Randomized comparison of interferon a and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon a and hydroxyurea. Leukemia 17 (2003) 1529-1537
54. Chronic Myeloid Leukemia Trialists' Collaborative Group. Interferon alpha versus chemotherapy for chronic myeloid leukemia: a meta analysis of seven randomized trials. J Natl Cancer Inst 89 (1997) 1616-1620
55. Sokal J.E., Gockerman J.P., and Bibner S.H. Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia. Leukemia Res 12 (1988) 453-458
56. Guilhot F., Dreyfus B., Brizard A., et al. Cytogenetic remissions in chronic myelogenous leukemia using interferon alpha2a and hydroxyurea with or without low dose cytosine-arabinoside. Leuk Lymphoma 4 (1991) 49-55
57. Kantarjian H.M., Keating M.J., Estey E.H., et al. Treatment of advanced stages of Philadelphia chrosomome-positive chronic myelogenous leukemia with Interferon-* and low-dose cytarabine. J Clin Oncol 10 (1992) 772-778
58. Kantarjian H., O'Brien S., Beran M., et al. Interferon alpha (IFN-A) and low-dose cytosine arabinoside (Ara-C) therapy in Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML). Blood 86 Suppl. 1 (1995) abs n°2105
59. Guilhot F., Chastang C., Michallet M., et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 337 (1997) 223-229
60. Guilhot F., Guerci A., Maloisel F., et al. Follow-up of 1047 patients with chronic myelogenous leukemia treated with interferon or interferon with cytarabine. Blood 90 Suppl. 1 (1997) Abs 2299
61. Baccarani M., Rosti G., De Vivo A., et al. A randomized study of interferon-* and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood 99 (2002) 1527-1535
62. Kühr T., Burgstaller S., Apfelbeck U., et al. A randomized study comparing interferon (IFNa) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML). Leuk Res 27 (2003) 405-411
63. Maloisel F., Guerci A., Guyotat D., et al. Results of a phase II trial of a combination or oral cytarabine ocfosfate (YNK01) and interferon-*2b for treatment of chronic myelogenous leukemia patients in chronic phase. Leukemia 16 (2002) 573-580
64. Rosti G., Bonifazi F., Trabacchi E., et al. A phase II study of a-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. Leukemia 17 (2003) 554-559
65. Cervantes F., Sureda A., Hernandez-Boluda J.C., et al. Interferona plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon. Haematologica 86 (2001) 1281-1286
66. Kühr T., Eisterer W., Apfelbeck U., et al. Treatment of patients with advanced chronic myelogenous leukemia with interferon-alpha-2b and continuous oral cytarabine ocfosfate (YNK01): a pilot study. Leuk Res 24 (2000) 583-587
67. Hochhaus A., Kreil S., Corbin A.S., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196
68. Lucy J.E., Jorgensen H.G., Mountford J.C., et al. Punish the parent not the progeny. Blood 105 (2005) 1862-1866
69. ®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia. Leuk Lymphoma 48 (2007) 497-505
70. Michallet M., Maloisel F., Delain M., et al. Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study. Leukemia 18 (2004) 309-315
71. Baccarani M., Martinelli G., Rosti G., et al. Imatinib an pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia. Blood 104 (2004) 4245-4251
72. Palandri F., Iacobucci I., Castagnetti F., et al. Front line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5 year outcome. Haematologica 93 (2008) 770-774
73. O'Brien S., Vallance S.E., Craddock C., et al. PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase chronic myeloïd leukemia. Blood 98 (2001) 3512a
74. Hehlmann R., Sau S., Lauseker M., et al. Randomized clinical trial for the optimization of Imatinib therapy by combination, dose escalation and transplantation. Designed first interim analysis of the German CML study IV. Haematologica 94 Suppl. 2 (2009) 0478
75. Rousselot P., Preudhomme C., Guilhot J., et al. Molecular responses of the SPIRIT phase III trial of the French CML group comparing Imatinib 400 mg to higher dose Imatinib or combination with interferon or cytarabine for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients. Haematologica 94 Suppl. 2 (2009) 1093
76. Alimena G., Breccia M., Luciano L., et al. Imatinib mesylate therapy in chronic myeloid leukemia patients in stable complete cytogenetic response after interferon-alpha results in a very high complete molecular response rate. Leuk Res 32 (2008) 255-261
77. Bonifazi F., de Vivo A., Rosti G., et al. Chronic myeloid leukemia and interferon-α a study complete cytogenetic responders. Blood 98 (2001) 3074-3081
78. Parmar S., Smith J., Sassano A., et al. Differential regulation of the p70 S6 kinase pathway by interferon α (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 106 (2005) 7